达托帕马布德鲁克斯泰康诱导免疫细胞死亡的特征
Sabrina Forveille1,2, Marion Leduc1,2, Allan Sauvat1,2
1Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Université Paris Saclay, Villejuif, France.
Cell stress
|August 13, 2025
概括
达托帕马布德鲁克斯泰坎 (Datopotamab deruxtecan) 是一种针对TROP2的抗体-药物联合体,通过传递细胞毒性有效载荷,有效地杀死癌细胞. 这种药物诱导免疫细胞死亡,并对非TROP2表达细胞表现出旁观者作用.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 抗体与药物联合体 (ADC) 是为向癌症治疗而设计的.
- 达托帕马布德鲁克斯泰康向与瘤相关的信号转换器2 (TROP2).
研究的目的:
- 为了研究达托帕马布deruxtecan的作用机制.
- 评估其细胞毒性作用和诱导免疫细胞死亡 (ICD).
主要方法:
- 利用了人类骨髓瘤U2OS细胞,这些细胞被改造成表达TROP2.
- 评估了细胞活力,CALR-GFP转位,细胞表面calreticulin暴露,HMGB1释放和ATP分泌.
- 同培养的TROP2表达细胞和父细胞,以评估旁观者效应.
主要成果:
- 在TROP2表达细胞中,但不是父细胞中,达托帕马布deruxtecan可降低活力.
- 该ADC触发了CALR-GFP转位和ICD的标志,包括卡莱蒂库林暴露,HMGB1释放和ATP分泌.
- 在与TROP2-阳性细胞共同培养的TROP2-阴性细胞上观察到旁观者抗瘤效应.
结论:
- 达托帕马布德鲁克斯泰康有效地将其细胞毒性有效载荷传递给TROP2表达的癌细胞.
- 该ADC诱导免疫细胞死亡的关键特征in vitro.
- 达托帕马布德鲁克斯泰坎表现出旁观者效应,表明更广泛的治疗潜力.
更多相关视频
08:02In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
Published on: September 23, 2021
2.7K
13:59High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
2.2K
相关概念视频
01:30Overview of Cell Death
7.7K
Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
7.7K
01:17The Extrinsic Apoptotic Pathway
6.6K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.6K
01:27Cytotoxic T Cells-mediated Immune Response
2.0K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
2.0K
01:18Autophagic Cell Death
3.6K
Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
3.6K
01:27Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660